|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: tolvaptan
| |||||||||||||||
Clinical Trials for: tolvaptanBioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact Status: Completed Condition: Healthy Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice Status: Active, not recruiting Condition: SIADH; Non-SIADH Hyponatremia; Non-Hyponatremia Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Status: Completed Condition: Ascites; Hepatic Cirrhosis Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management Status: Recruiting Condition: Heart Failure Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia Status: Recruiting Condition: Liver Cirrhosis; Hyponatremia Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Status: Terminated Condition: Hyponatremia; Dilutional Hyponatremia; Inappropriate ADH Syndrome Tolvaptan for Ascites in Cirrhotic Patients Status: Suspended Condition: Ascites; Cirrhosis 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Status: Active, not recruiting Condition: Autosomal Dominant Polycystic Kidney Disease Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Status: Completed Condition: Autosomal Dominant Polycystic Kidney Disease Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE) Status: Not yet recruiting Condition: Acute Heart Failure Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otsuka America Pharm | SAMSCA | tolvaptan | TABLET; ORAL | 022275 | May 19, 2009 | RX | No | 5,258,510 | Y | Y | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Otsuka America Pharm | SAMSCA | tolvaptan | TABLET; ORAL | 022275 | May 19, 2009 | RX | No | 5,753,677 | <disabled> | METHOD OF TREATING HYPONATREMIA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Otsuka America Pharm | SAMSCA | tolvaptan | TABLET; ORAL | 022275 | May 19, 2009 | RX | No | <disabled> | NEW CHEMICAL ENTITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Otsuka America Pharm | SAMSCA | tolvaptan | TABLET; ORAL | 022275 | May 19, 2009 | RX | Yes | 5,258,510 | Y | Y | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
